Nxera Pharma Co.,Ltd.
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026
Filed with TSE ·
On 6ix: 6ix.com/news/nxera-pharma-operational-highlights-and-consolidated-results-for-the-third-quarter-2026
Watch Nxera Pharma's latest callNxera Pharma (Tokyo:4565) Q2 2026 Earnings Call · Replay · Aug 7Read the transcript of Nxera Pharma (Tokyo:4565) Q2 2026 Earnings Call6ix is reading this filing.
View original source (TDnet)Nxera Pharma Co., Ltd. on 6ix
In the deck
Story so far
Earlier from Nxera Pharma
- Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets
- Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
- Introduction of the Executive Officer Performance Stock Option Plan and Issuance of Stock Acquisition Rights Under the Plan
- Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ Across Eight Asia-Pacific Markets
- Nxera Announces Successful Resolution of miniG Patent Infringement Action
Follow Nxera Pharma into a list and get an email when it puts out news.
Follow Nxera Pharma